-+ 0.00%
-+ 0.00%
-+ 0.00%

Inhibrx to webcast Phase 1/2 update on ozekibart plus FOLFIRI in colorectal cancer

PUBT·04/20/2026 21:22:15
Listen to the news
Inhibrx to webcast Phase 1/2 update on ozekibart plus FOLFIRI in colorectal cancer
  • Inhibrx scheduled a webcast for April 21, 2026, to present a clinical update from its Phase 1/2 study of ozekibart (INBRX-109) with FOLFIRI in late-line colorectal cancer.
  • Results have not yet been presented; disclosure is planned during the upcoming webcast.
  • Ozekibart is designed to trigger tumor-biased cell death through DR5 activation, positioning the program as a potential new option in hard-to-treat solid tumors.
  • In a separate registrational chondrosarcoma trial, ozekibart previously showed a meaningful improvement in delaying disease worsening versus placebo, supporting its broader development strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.